Targeting the Werner syndrome protein in microsatellite instability cancers: mechanisms and therapeutic potential

Area of Science:

• Oncology
• Genetics
• Molecular Biology

Background:

• Microsatellite instability (MSI) is a hallmark of cancers with deficient DNA mismatch repair.
• Tumors with MSI exhibit a dependency on the Werner syndrome protein (WRN) for maintaining genomic stability.
• This dependency makes WRN a promising therapeutic target for precision oncology.

Purpose of the Study:

• To review the molecular mechanisms of WRN dependency in MSI cancers.
• To explore the therapeutic potential of WRN inhibition as a cancer treatment strategy.
• To discuss the combination of WRN inhibitors with other therapies.

Main Methods:

• Literature review of preclinical studies on WRN inhibitors in MSI cancers.
• Analysis of molecular mechanisms underlying WRN's role in genomic stability.
• Evaluation of combination therapy strategies involving WRN inhibitors.

Main Results:

• WRN inhibitors induce synthetic lethality, selectively causing DNA damage and cell death in MSI tumors.
• Preclinical data suggest enhanced efficacy of WRN inhibitors when combined with DNA damage response inhibitors or immunotherapy.
• WRN inhibition demonstrates potential as a monotherapy or combination treatment.

Conclusions:

• WRN inhibition is a promising therapeutic strategy for MSI cancers.
• Targeting WRN offers a precision oncology approach with potential to improve patient outcomes.
• Combination therapies may further enhance the effectiveness of WRN inhibitors in treating MSI tumors.